Marshall Wace, LLP Regeneron Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

$72.2 Billion
Q2 2024

A detailed history of Marshall Wace, LLP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 58,873 shares of REGN stock, worth $61.4 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

58,873

Previous 200,387 70.62%

Holding current value

$61.4 Million

Previous $193 Million 67.92%

% of portfolio

0.09%

Previous 0.3%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $125 Million - $152 Million	-141,514 Reduced 70.62%	58,873 $61.9 Million
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $95.6 Million - $105 Million	105,861 Added 111.99%	200,387 $193 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $8.33 Million - $9.48 Million	-10,751 Reduced 10.21%	94,526 $83 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $26.5 Million - $32.3 Million	-38,231 Reduced 26.64%	105,277 $86.6 Million
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $36.9 Million - $43.8 Million	52,710 Added 58.05%	143,508 $103 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $55.2 Million - $67.1 Million	81,098 Added 836.06%	90,798 $74.6 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $3.95 Million - $4.29 Million	5,595 Added 136.3%	9,700 $7 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $27.5 Million - $34.7 Million	-47,950 Reduced 92.11%	4,105 $2.83 Million
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $26.4 Million - $35.6 Million	48,188 Added 1246.13%	52,055 $30.8 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $74.5 Million - $87.4 Million	-125,161 Reduced 97.0%	3,867 $2.7 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $13.6 Million - $16.8 Million	25,056 Added 24.1%	129,028 $81.5 Million
Q3 2021 Nov 15, 2021	BUY	$574.03 - $680.96 $18.1 Million - $21.5 Million	31,520 Added 43.5%	103,972 $62.9 Million
Q2 2021 Aug 13, 2021	BUY	$472.8 - $558.54 $25.7 Million - $30.4 Million	54,384 Added 301.0%	72,452 $40.5 Million
Q1 2021 May 17, 2021	BUY	$446.73 - $548.2 $6.9 Million - $8.47 Million	15,448 Added 589.62%	18,068 $8.55 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $1.25 Million - $1.59 Million	2,620 New	2,620 $1.27 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $7.23 Million - $8.73 Million	-13,270 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$493.32 - $643.92 $6.55 Million - $8.54 Million	13,270 New	13,270 $8.28 Million
Q1 2020 May 15, 2020	SELL	$336.18 - $494.43 $8.83 Million - $13 Million	-26,276 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$274.13 - $376.51 $4.79 Million - $6.57 Million	17,461 Added 198.08%	26,276 $9.87 Million
Q3 2019 Nov 14, 2019	SELL	$273.46 - $318.39 $30.7 Million - $35.8 Million	-112,360 Reduced 92.73%	8,815 $2.45 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $36.3 Million - $50.3 Million	121,175 New	121,175 $37.9 Million
Q1 2019 May 14, 2019	SELL	$372.08 - $439.57 $484,820 - $572,759	-1,303 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $437,573 - $525,161	1,303 New	1,303 $487,000
Q3 2018 Nov 14, 2018	SELL	$351.14 - $408.51 $3.06 Million - $3.56 Million	-8,703 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$284.6 - $344.99 $2.48 Million - $3 Million	8,703 New	8,703 $3 Million

Others Institutions Holding REGN

# of Institutions

1,463

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Regeneron Pharmaceuticals, Inc. Transaction History